Södertälje, Sweden

Lena Axelson-Larsson

This inventor holds 3 USPTO granted patents. Top assignee: Astrazeneca Ab. Active years: 2008-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lena Axelson-Larsson. Retrieved from https://idiyas.com/inventor/lena-axelson-larsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 66.7

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 35(Granted Patents)


Location History:

  • Södertälje, SE (2008)
  • Sodertälje, SE (2008)
  • Södertäljc, SE (2012)

Company Filing History:


Years Active: 2008-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Lena Axelson-Larsson: Pioneering Swedish Inventor

Introduction: Lena Axelson-Larsson is a renowned Swedish inventor known for her groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Lena Axelson-Larsson holds several patents in the areas of renewable energy, sustainable materials, and medical devices, showcasing her versatility and ingenuity in inventing.

Career Highlights: With a career spanning over two decades, Lena Axelson-Larsson has worked with leading research institutions and universities to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout her career, Lena Axelson-Larsson has collaborated with top companies, innovative startups, and talented individuals to bring her inventions to life and create real-world applications for her groundbreaking ideas.

Conclusion: Lena Axelson-Larsson's passion for innovation and her dedication to creating a positive change through her inventions have solidified her reputation as a pioneering inventor in Sweden and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…